New Heart Treatment Shows Promise for Complex Cases
A new injectable therapy called Amvuttra is helping people with a rare heart condition live longer, even those with complicated health challenges. Real-world studies show it works across diverse patient groups, bringing hope to thousands.
People facing a rare and devastating heart condition just got powerful new evidence that an approved treatment can help them live longer and healthier lives.
Amvuttra, an injectable therapy given every three months, has shown consistent benefits for patients with ATTR-CM, a disease where toxic protein clumps damage heart tissue. New analyses presented at a major cardiology conference in May 2026 confirm the treatment works even in people with complicated cases, including those with irregular heart rhythms and low blood pressure.
The findings come from a deep dive into data from the HELIOS-B trial, which studied over 600 adults with ATTR-CM. About two-thirds of participants had atrial fibrillation, an abnormal heart rhythm that signals more advanced disease. Even in these high-risk patients, Amvuttra significantly reduced deaths and major heart events compared to a placebo.
Dr. Scott Solomon, a Harvard Medical School professor, says the results support using Amvuttra as a first-line treatment for a broad range of patients. The therapy works by reducing levels of the troublesome transthyretin protein that causes the disease.
What makes these findings particularly encouraging is how well the treatment worked across the board. Women, who have historically been left out of many heart disease studies, saw the same benefits as men. Patients taking other medications, including different ATTR-CM therapies and standard heart failure drugs, still experienced positive results.
Researchers also tackled a common concern about the treatment. Because the transthyretin protein helps transport vitamin A through the body, doctors worried that lowering it might cause vision problems. An analysis covering more than 25,000 patient-years of treatment found that vitamin A-related side effects were rare and no more common than in people taking a placebo.
The Bright Side: Beyond these encouraging trial results, researchers are already looking ahead. A new five-year study called DemonsTTRate is now recruiting 2,000 patients to track how Amvuttra performs in everyday clinical practice, not just in controlled trials. This real-world data will help doctors understand exactly how to use this therapy to give their patients the best possible outcomes. Meanwhile, the company behind Amvuttra is developing an even better next-generation version called nucresiran.
For families facing ATTR-CM, a diagnosis that once meant limited options, these advances represent genuine hope backed by solid science.
More Images
Based on reporting by Google: new treatment approved
This story was written by BrightWire based on verified news reports.
Spread the positivity!
Share this good news with someone who needs it
